Equillium (EQ) Net Margin (2023 - 2024)
Equillium (EQ) posted quarterly Net Margin of 132.81% for Q4 2024, down 9412.0% year-over-year from 1.43% in Q1 2024, and down 230628.31% quarter-over-quarter from 0.06% in Q3 2024.
Powered by 
Analysis
Equillium (EQ) Net Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has reported Net Margin for 2 consecutive years, with 132.81% the latest figure, recorded in Q4 2024.
- In Q4 2024, Net Margin fell 9412.0% year-over-year to 132.81%; the TTM figure through Sep 2025 stood at 670.67% (down 65796.0% YoY), while the FY2024 annual figure was 19.73%, up 2062.0% from the prior year.
- Net Margin eased to 132.81% in Q4 2024 per EQ's latest filing, from 0.06% in the prior quarter.
- Across five years, Net Margin topped out at 3.38% in Q2 2024 and bottomed at 132.81% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -86.86% |
| Sep 30, 2024 | -0.06% |
| Jun 30, 2024 | 3.38% |
| Mar 31, 2024 | -25.58% |
| Dec 31, 2023 | 10.35% |
| Sep 30, 2023 | -41.87% |
| Jun 30, 2023 | -36.64% |
| Mar 31, 2023 | -44.82% |